Inhibition of the inflammasome via NLR family pyrin domain containing 3 (NLRP3) blockers counteracts the pro‐atherosclerotic effects of TET2 mutations by reducing IL‐1β–mediated endothelial P‐selectin expression and subsequent macrophage recruitment,[45] thus providing a molecular link between CHIP and atherosclerosis. Here, NLRP3 is linked to atherosclerosis.